Original Source(s)
Related Content
FDA expands gastroesophageal cancer options
Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.
August 25, 2026
-
2 min
Narrow DCIS Margins May Not Always Warrant Reexcision
An ancillary analysis found less than 2-percentage-point differences in 10-year recurrence across margin thresholds, with no statistically significant adjusted association.
July 20, 2026
-
6 min
Retained silk may underlie late postvasectomy fistula
Surgery and histopathology identified retained silk ligature with chronic inflammation at the site of a rare fistula presenting 3 years following vasectomy.
September 18, 2026
-
4 min